John T Letsinger is a notable inventor based in West Haven, CT (US). He has made significant contributions to the field of diabetes research through his innovative work on aminopeptidases. With a total of 2 patents, Letsinger's inventions focus on the modulation of insulin resistance.

Latest Patents

Letsinger's latest patents include the development of a glucose transporter vesicle aminopeptidase. This aminopeptidase is a crucial component of GLUT4-containing vesicles in their natural state and plays a role in cleaving insulin. The claimed protein has an apparent molecular weight of approximately 110 kD in its deglycosylated form, with a predicted molecular weight of 117,239 Daltons. It features specific amino acid sequences, including Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala (SEQ ID NO: 1) and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Met (SEQ ID NO: 2). Additionally, it reacts with antibodies produced against the peptide identified as SEQ ID NO: 1. The patent also claims modulators of the aminopeptidase's activity and methods for treating syndromes of insulin resistance, including diabetes.

Career Highlights

John T Letsinger is currently associated with Bayer Corporation, where he continues to advance his research in the field of diabetes. His work has been instrumental in understanding the mechanisms of insulin resistance and developing potential treatments.

Collaborations

Letsinger has collaborated with notable colleagues, including Wallace Haigh and Donna Guralski, to further enhance the impact of his research.

Conclusion

John T Letsinger's innovative contributions to diabetes research through his patents and collaborations highlight his commitment to improving health outcomes. His work continues to pave the way for advancements in the treatment of insulin resistance and diabetes.